NextPoint Could Treat PD-L1 Negative Cancer Patients With HHLA2-Targeted Approach

 
• By Ayisha Sharma

Emerging Company Profile: Backed by strong academic talent and a recent $80m fundraising, the US biotech is on a mission to address the unmet medical need in PD-L1 negative cancer by targeting the HHLA2 pathway.  

Emerging Company Profile: NextPoint Therapeutics
PD-L1 Negative Cancer Patients Have Fewer Treatment Options • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs